

Significance of Modern Diagnostic Methods of Sepsis

¹Nuruzova Z.A.,

²Yodgorova N.T.,

³Mamanov J.B.

Tashkent Medical academy

¹Head of the Department of Microbiology, Virology, Immunology of TMA

²Associate Professor of the Department of Microbiology, Virology, Immunology of

TMA, Ph.D. Yodgorova1977@bk.ru

³Second Year Student of Treatment Faculty of TMA,

mamanovjamshid131@gmail.com

Abstract

In this literature analysis the treatment measures of sepsis in recent years (2012-2022), modern diagnostic methods, the importance of modern serological, molecular-biological, molecular-genetic methods, their possibilities and advantages, and effective treatment methods are widely covered. For example, real-time PCR (Real-Time PCR), immuno-PCR, correlation CMG classifier, component analysis (PCA), Anti-inflammatory therapy, Tumor Necrosis Factor (TNF-a), which are considered one of the new, modern forms of PCR, were conducted in such patients As a result of many clinical trials, several pharmacological agents are highly effective, for example: glucocorticoids, non-steroidal anti-inflammatory drugs, monoclonal antibodies and platelet-activating, immune-enhancing agents.

Keywords: Sepsis, Streptococcus, PZR, correlation CMG classifier, component analysis (PCA), Anti-inflammatory therapy, Tumor Necrosis Factor (TNF-a).

Introduction

Sepsis is a potentially fatal organ dysfunction brought on by the host's systemic overreaction to infection. It causes multiple organ failure and subsequent infections, and in cases of complex septic shock, its fatality can exceed 40% [1,2]. One of the leading causes of death is ARDS, which is its most prevalent complication [1,2].

Recent research has revealed that circRNAs are distinct non-coding regulatory RNAs that feature a circular structure made of covalent bonds rather than a 5' end cap and 3' end poly A tail [3,4].

Human cells contain many more circular RNAs than mRNAs [3] It is well known that diabetics are more likely to contract infections (Weixin Guo). It was contrasted to the entire populace, particularly the elderly. 1–3 individuals with diabetes mellitus (DM) have been found to have a higher frequency of bacteremia, risk of pneumonia, TB,

urinary tract, skin, and fungal infections as well as hospital acquired post-operative infections,¹⁻⁴ as compared to non-DM individuals.

We used a population-based retrospective prospective study design to examine whether type 2 diabetes (T2D) has a negative impact on the primary outcome following sepsis, which did not necessitate admission to an intensive care unit (ICU). Akinosoglou, Karolina Recent years have seen an increase in the prevalence of sepsis, which has become a global public health concern. The malfunction of a patient's immune response to infection, known as sepsis, results in functional impairment of the organ systems (YupengLei).

A succession of host responses to microbial assault can explain the complicated clinical events that make up sepsis. The systemic reactions that follow are characterized by the early emergence of proinflammatory cytokines, which cause a hyper-inflammatory phase that is followed by septic shock and patient mortality. The current investigation has shown that antibiotics are not sufficient in and of themselves to regulate the intricate process of sepsis. Furthermore, the overuse and prolonged administration of antibiotics can make pathogens resistant to them. Additionally, immunosuppressive drugs are selective and apply a targeted strategy to a particular study population (Juliana Usmani).

Etiology

Associated with a dysregulated host response to infection, sepsis is a clinical syndrome that poses a serious risk to life. The lung is the most frequently failing organ among the wounded organs due to its great vulnerability (Fangbo Zhang).

Pathogens

Sepsis can happen with any infection, regardless of the pathogen present. Sepsis can be brought on by bacteria, fungi, parasites, or viruses, however bacteria are the most frequently found cause. The microorganism that causes sepsis is still unknown or uncertain in 30 to 50 percent of patients (Elsevier B.V.).

To look into the occurrence of early-onset newborn sepsis and pinpoint the major pathogens in Kuwait throughout a 5-year period.

Methods:

At Kuwait's primary maternity hospital, blood samples were taken from all infants with any clinical or laboratory feature suggestive of sepsis. Early-onset neonatal infection cases are those in which a single potentially pathogenic organism is cultured from blood or cerebrospinal fluid of infants younger than 7 days of age, along with clinical or laboratory signs consistent with infection.

Results:

Every 1000 live births, there were 2.7 (95% confidence interval (CI) 2.3-3.2) episodes of early-onset neonatal infection. 13.1% of cases resulted in death (95% CI: 8.6-18.9%). Infections caused by Group B Streptococcus (GBS) were responsible for 38.1% of infections in the first two days of life but 17.6% of infections in newborns younger than 7 days (incidence 0.48 per 1000 live births). Over the course of the study, there were no appreciable changes in the incidence of early-onset GBS infection or Escherichia coli infection.

Conclusions:

The majority of early-onset infections were caused by GBS, despite the fact that its frequency was very low. It is important to reinforce intrapartum antibiotic prophylaxis against GBS. According to Abdullah Al-Taïar, there is no evidence to support an increase in early-onset infections brought on by non-GBS pathogens like E. coli in the last five years. With 3.5 million citizens, Kuwait is a small nation.

The majority of births take place in medical facilities, and neonatal and infant mortality rates are comparable to those of other affluent nations at roughly 5.6 and 9 per 1000 live births, respectively.

The study was carried out at the Kuwait Maternity Hospital, a significant tertiary facility where around one-third of all births in the nation take place. This hospital performs over 12 000 deliveries each year. Only about 2.5% of live births are under 1500 g in weight. Ampicillin has been administered intrapartum as GBS infection prevention using a risk-based approach to moms who are at high risk of GBS infection since 2005. When a newborn has a suspected infection, antibiotics are started right once, especially if there are risk factors such a premature membrane rupture or a fever in the mother. Ampicillin and amikacin are typically used as the first lines of empirical antibiotic treatment, with clinical and laboratory results later on dictating the course of action (AbdullahAl-Taïar).

Clinics

Damage to the body results from a microbial attack or an injury to the host, and invasive microbes emit molecules known as pathogen-associated molecular patterns (PAMPs) or disease-associated molecular patterns (DAMPs). These molecular patterns are recognized by pattern recognition receptors (PRRs) on innate immune cells including monocytes and macrophages, which results in a pro-inflammatory state. TNF-, IL-1, IL-6, and IL-8 are the pro-inflammatory mediators of sepsis that are most frequently seen. The proinflammatory phase is typically followed by the hyperinflammatory phase, which is characterized by the development of the hyperinflammatory cytokines IL-4, IL-1ra, IL-10, and TGF-1 [5]. IL-6 and TNF-

control the release of IL-10 from monocytes [6]. IL-10's main action appears to be to reduce inflammation (Juveria Usmani).

Pathophysiology of sepsis

A number of sepsis pathophysiology are triggered by microbial injury to the host's body, which results in infection and a modification of the immune response. This shows up as a proinflammatory condition followed by a hyperinflammatory phase, SIRS, or CARS, which is demonstrated by the emergence of various organ dysfunction. In this immunosuppressive stage, septic shock and death are possible outcomes. With a high possibility of recovery, early detection and management of the hyperinflammatory phase can lower the risk of sepsis progression.

Systemic inflammatory response syndrome (SIRS), which is the hyperinflammatory phase, leads to compensatory anti-inflammatory response syndrome (CARS), also known as "immunoparalysis." Following the immunosuppressive phase, multiple organ dysfunctions (MODS) appear. This condition is sometimes referred to as septic shock, which always results in death.

According to Juveria Usmani, SIRS bases its definition of sepsis on the manifestation of two or more criteria [8].

One of the main effects of sepsis is abnormal heart function. In response to the increased production of inflammatory mediators and free radicals during sepsis, the cardiovascular system's function is disrupted.

The carriers to decrease myocardial activity, cardiac enzyme reduction, hypotension, and hypoxia during sepsis are cytokines such TNF-, IL-1, IL-6, Toll-like Receptors (TLRs), and NO. Vasodilation and defective diastole and systole impair the ability of the left ventricle to contract and fill with blood (Juliana Usmani). Fig. 1 illustrates various roles of herbal medicines to treat sepsis.




Fig. 1. Pharmacological activity of herbal compounds for sepsis treatment.

Various roles of herbal medicines to treat sepsis has been produced in this figure depicting the immunological and non-immunological activities of medicinal plants at different organs.

Pathogenesis

Beyond the type of infection and the initial host response, the pathophysiology of sepsis is intricate and includes diverse aspects of inflammation, coagulation activation, the vascular endothelium and complement system, immunological suppression, and microbiome changes (Elsevier B.V.).

According to a recent study, sepsis can result in up to 40% of hospital deaths. The primary cause of sepsis is its complicated process, which also involves gene polymorphism, endoplasmic reticulum stress, an imbalance in the inflammatory response, immunological dysfunction, and coagulation system disorders. Jin Jie Bao The development of reactive oxidizing species including superoxide, hydrogen peroxide, and hydroxyl radicals as free radicals causes oxidative stress, whereas the elimination of antioxidant scavengers like catalase, superoxide dismutase (SOD), vitamin C and vitamin E, and reduced glutathione (GSH) causes free radical generation. Reactive oxygen species are produced by a number of physiological processes during septic shock, including the respiratory electron transport chain, xanthine oxidase activation brought on by ischemia and reperfusion, neutrophil activation, and arachidonic acid metabolism. This enables the membrane-bound NADPH oxidase and molecular oxygen to interact with the activated neutrophil to form hydrogen peroxide, which in turn yields superoxide and nitric oxide as free radicals. Nitric oxide (NO), which is made by L-arginine, is created by nitric oxide synthase (NOS), which is increased by the activation of nuclear factor κ B (NF- κ B) and lipopolysaccharide (LPS) treatment. Nitric oxide then interacts with superoxide to form peroxynitrite, a potent oxidant, which is followed by hydroxyl radicals [9]. Additionally, a crucial terminal enzyme in the electron transport chain is suppressed, which results in the production of hydrogen peroxide (H_2O_2) and elevated NO levels [10]. Increased intracellular O_2 levels (super-oxide radicals) are ultimately brought on by this [11]. Through the occurrence of lipid peroxidation and the subsequent production of free radical species, which results in membrane depolarization and altered protein structures as well as altered cellular respiration, oxidative stress damages DNA and proteins. This results in cell death, cytochrome c release, mitochondrial damage, and other effects (Juveria Usmani).

Diagnostic Methods

Multiple datasets and times were used to evaluate the CMG classifier's diagnostic performance. Principal component analysis (PCA) was also employed to evaluate the capacity to distinguish between sepsis and other critical disorders.

We examined the CMG score across various sepsis subgroups and investigated the relationship between the CMG classifier and clinical parameters (such as age, APACHEII) or phenotypes. The predictive ability of the CMG classifier was tested using univariate and multivariate logistic regression analysis to see if it remained unaffected by other clinical variables.

Immune cell infiltration

We separately combined the GEO and ArrayExpress datasets for further analysis in order to increase statistical power in immune microenvironment study. The ComBat function in the "sva" R package was used to adapt the batch effects for various datasets. Using the CIBERSORTx tool and the ssGSEA algorithm, it was possible to estimate the relative number of invading immune cells. We look into how the immune system differs between the various CMG subgroups. Further Spearman correlation studies were conducted to examine the interaction between immune cells and CMG classifier/hub CMGs.

Immune and molecular pathways

In order to assess the level of enrichment of pre-specified biological processes (immune/inflammation-related pathways, apoptosis), gene set variation analysis (GSVA) based on a particular dataset was used (Supplementary material 2). We investigate the variations in biological functions among various CMG patterns. Then, in order to further illuminate the relationship between CMG classifier/hub CMGs and some related biological pathways, we carried out a correlation analysis.

Analyses of the cytokines

From earlier reviews, a panel of 18 inflammatory cytokines was developed [15]. We contrasted the amounts of cytokine expression in various CMG subtypes. Additionally, we used Spearman correlation analyses to look at the relationship between CMG classifier/hub CMGs and important cytokines.

Statistical analysis

SPSS 22 and R software (version 4.0.4) were used to conduct the statistical analysis. To assess the statistical difference using two-tailed, Student's t-tests, Wilcoxon tests, Chi-square tests, and Kruskal-Wallis tests were used. Using a receiver operating characteristic (ROC) curve and area under the curve (AUC), diagnostic and prognostic performance was assessed. Except in cases where a specific p value has been provided, statistical significance was defined as p 0.05 (two-sided) (Zhen Chen).

Treatment

There are currently no effective medications or therapies for sepsis-induced ALI. Anti-inflammatory therapy is a vital and successful form of medicine. It's (Fangbo Zhang). Sepsis can be effectively treated with antibiotics and fluid resuscitative therapy. In contrast, sepsis and associated consequences are still very common in intensive care units. Several pharmacological agents, including glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), antiendotoxin monoclonal antibodies, platelet activating factor antagonist, interleukin-1 receptor antagonist, and tumor necrosis factor (TNF-), were used in numerous clinical trials.

Antagonist. Antibiotics

Previous studies concentrated on the use of antibiotics in clinical settings to treat sepsis. The role of several antibiotics in the treatment of septic shock appears to enhance the immune response through various mechanisms, improving survival [16]. For instance, imipenem, an antibiotic in the carbapenem class, has been found to lower sepsis-related levels of IL-6, IL-10, and TNF- [17]. When compared to imipenem and 5% dextrose water solution, the administration of a combination of gentamicin, ciprofloxacin, and clindamycin did not significantly differ in cytokine levels at any of the three time points [18]. using antibiotics like those in Fig. 1. Sepsis' pathophysiology. A number of sepsis pathophysiology are triggered by microbial injury to the host's body, which results in infection and a modification of the immune response. This shows up as a proinflammatory condition followed by a hyperinflammatory phase, SIRS, or CARS, which is demonstrated by the emergence of various organ dysfunction. In this immunosuppressive stage, septic shock and death are possible outcomes. In septic rats, piperacillin/tazobactam decreased the levels of IL-6, HMGB-1, and TNF- [19]. Doxycycline and ceftriaxone also reduced the levels of cytokines like IL-1, IL-6, TNF-, and myeloperoxidase (MPO), which increased survival in septic mice [20]. According to a study, imipenem with cyclophosphamide increased the survival rate in an animal sepsis model [21]. In contrast, research has also shown that imipenem does not increase survival in septic animals who received antibiotics both before and after surgery at various times [22]. Additionally, the overuse and prolonged administration of antibiotics can make pathogens resistant to them [23,24]. It is clear that antibiotics are not sufficient in and of themselves to regulate the intricate mechanisms of sepsis. Additionally, the effect of antibiotic therapy in sepsis seems to be unclear.

Corticosteroids

In Fig. 2, antibiotics used in sepsis are underlined to clarify their mechanism at various stages of sepsis. Secondary infections are caused by the use of corticosteroids [51]. According to a review, corticosteroid medication in sepsis decreases mortality but

greatly increases the risk of neuromuscular weakening [52]. According to research on corticosteroids, they can control immune response and lower blood pressure brought on by sepsis.




Fig. 2. Antibiotics used during different phases of sepsis.

Elucidation of antibiotics with their mechanism at different phases of sepsis. IL: Interleukin; TNF: Tumor necrosis factor; TGF: Transforming growth factor; CRP: C-reactive protein; SIRS: systemic inflammatory response syndrome; CARS: compensatory antiinflammatory response syndrome; MODS: Multiple organ dysfunctions; PAMPs: Pathogen associated molecular patterns; DAMPs: disease associated molecular patterns; HMGB-1: High mobility group box [53]. However, due to a lack of information regarding the survival benefits, some medical professionals disagree with the recommendation of corticosteroids (Juliana Usmani).

Twenty-two individuals were retrospectively determined to have aseptic inflammation out of all patients in the study group who had started taking antibiotics for the treatment of suspected sepsis. That is, despite the lack of an infection, roughly one in four individuals in the current sample were at risk for antibiotic-associated side effects. This emphasizes how challenging it is to use bedside universally accepted consensus sepsis definitions. Adverse medication reactions, the potential for additional opportunistic infections, disturbance of the microbiome, and antimicrobial resistance are among side

effects linked with antibiotic use. ICU patients frequently have antibiotic-associated side effects, which is partially attributable to the underlying severe disease that makes organ injury more susceptible. On the other hand, it's important to take into account the negative effects of failing to diagnose sepsis, delaying the use of the proper antibiotics, and missing out on possibilities for source control.

So, in a cohort of ICU patients receiving antibiotics, our goal was to ascertain whether there were variations in gene expression that could precisely distinguish between sepsis and aseptic inflammation. In this sample, all of whom had received antibiotic treatment within the previous 24 hours by the attending ICU clinicians for suspected infection, we discovered 53 DEGs that could accurately distinguish between sepsis with a positive blood culture and aseptic inflammation. The biological processes linked to infection were overrepresented, in line with the biological plausibility of this signature (for example, granulocyte chemotaxis and migration, T cell proliferation and activation, and fever production). In a validation cohort, the discovered transcriptome signature retained good accuracy (Kerina J.). Denny.

Conclusion

In conclusion, it can be said that the relevance of complications that occur with sepsis in medicine remains high. In the diagnosis of sepsis, real-time PCR, immuno-PCR, correlation CMG classifier, component analysis (PCA) methods are widely used. In the treatment of sepsis, Anti-inflammatory therapy, Tumor Necrosis Factor (TNF- α) Anti-inflammatory therapy remains important and effective. As a result of many clinical trials conducted in such patients, the use of several pharmacological agents, for example: glucocorticoids, non-steroidal anti-inflammatory agents, monoclonal antibodies, and platelet-activating, immune-enhancing agents, leads to positive results.

References

1. AbdullahAl-Taiar, MajedaS.Hammoud, LukmanThalib, DavidIsaacs//Pattern and etiology of culture-proven early-onset neonatal sepsis: a five-year prospective study/<http://dx.doi.org/10.1016/j.ijid.2011.05.004>.
2. Akil, H, Gordon, J, Hen, R, Javitch, J., Mayberg, H., McEwen, B., Meaney, M.J., Nestler, E.J., 2018. Treatment resistant depression: a multi-scale, systems biology approach. *Neurosci. Biobehav. Rev.* 84, 272–288. <https://doi.org/10.1016/j.neubiorev.2017.08.019>.
3. Anderson, S.T., Commins, S., Moynagh, P., Coogan, A.N., 2016. Chronic fluoxetine treatment attenuates post-septic affective changes in the mouse. *Behav. Brain Res.* 297, 112–115. <https://doi.org/10.1016/j.bbr.2015.10.011>.
4. Anderson, S.T., Commins, S., Moynagh, P.N., Coogan, A.N., 2015. Lipopolysaccharide-induced sepsis induces long-lasting affective changes in the mouse. *Brain Behav. Immun.* 43, 98–109. <https://doi.org/10.1016/j.bbi.2014.07.007>.

-
5. Calsavara, A.C., Rodrigues, D.H., Miranda, A.S., Costa, P.A., Lima, C.X., Vilela, M.C., Rachid, M.A., Teixeira, A.L., 2013. Late anxiety-like behavior and neuroinflammation in mice subjected to sublethal polymicrobial sepsis. *Neurotox. Res.* 24, 103–108. <https://doi.org/10.1007/s12640-012-9364-1>.
 6. Denny KJ, Cotta MO, Parker SL, Roberts JA, Lipman J. The use and risks of antibiotics in critically ill patients. *Expert Opin Drug Saf* 2016;15:667–78. <https://doi.org/10.1517/14740338.2016.1164690>.
 7. Duncan CF, Youngstein T, Kirrane MD, Lonsdale DO. Diagnostic challenges in Sepsis. *Curr Infect Dis Rep* 2021;23. <https://doi.org/10.1007/s11908-021-00765-y>.
 8. Elsevier B.V//Immunopathophysiology of human sepsis/eBioMedicine 2022;86:104363 <https://doi.org/10.1016/j.ebiom.2022.104363>
 9. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock 2021. *Crit Care Med* 2021;49:e1063–143. <https://doi.org/10.1097/CCM.0000000000005337>.
 10. Fangbo Zhang, Feifei Guo, Yi Zhang, He Xu, Yuling Liu, Longfei Lin, Hui Li, Hongjun Yang, Luqi Huang//Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19/journal homepage: www.elsevier.com/locate/phymed
 11. Gregoriano C, Heilmann E, Molitor A, Schuetz P. Role of procalcitonin use in the management of sepsis. *J Thorac Dis* 2020;12:S5–15. <https://doi.org/10.21037/jtd.2019.11.63>.
 12. Gupta S, Sakhuja A, Kumar G, McGrath E, Nanchal RS, Kashani KB. Culture-negative severe Sepsis: Nationwide trends and outcomes. *Chest* 2016;150:1251–9. <https://doi.org/10.1016/j.chest.2016.08.1460>.
 13. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners. *J Biomed Inform* 2019;95:103208. <https://doi.org/10.1016/j.jbi.2019.103208>.
 14. Heffernan AJ, Denny KJ. Host diagnostic biomarkers of infection in the ICU: where are we and where are we going? *Curr Infect Dis Rep* 2021;23:4. <https://doi.org/10.1007/s11908-021-00747-0>.
 15. Investigators A, Group ACT, Peake SL, Delaney A, Bailey M, Bellomo R, et al. Goal-directed resuscitation for patients with early septic shock. *N Engl J Med* 2014;371: 1496–506. <https://doi.org/10.1056/NEJMoa1404380>.
 16. Jackson, J.C., Pandharipande, P.P., Girard, T.D., Brummel, N.E., Thompson, J.L., Hughes, C.G., Pun, B.T., Vasilevskis, E.E., Morandi, A., Shintani, A.K., Hopkins, R.O., Bernard, G.R., Dittus, R.S., Ely, E.W., 2014. Depression, post-traumatic stress disorder, and functional disability in survivors of critical illness in the BRAIN-ICU

study: a longitudinal cohort study. *Lancet Respir. Med.* 2, 369–379. [https://doi.org/10.1016/S2213-2600\(14\)70051-7](https://doi.org/10.1016/S2213-2600(14)70051-7).

17. Joanna L. Spencer-Segal, Benjamin H. Singer, Klaudia Laborc, Khyati Somayaji, Stanley J. Watson, Theodore J. Standiford, Huda Akil//Sepsis survivor mice exhibit a behavioral endocrine syndrome with ventral hippocampal dysfunction/<https://doi.org/10.1016/j.psyneuen.2020.104679>

18. Junjie Bao, Yutao Zha, Shi Chen, Jun Yuan, Jiejie Qiao, Limian Cao, Qigang Yang, Miao Liu, Min Shao//The importance of serum LMAN2 level in septic shock and prognosis prediction in sepsis patients/<http://www.sciencedirect.com/science/journal/24058440>.

19. Juveria Usmani, Tahira Khan, Razi Ahmad, Manju Sharma//Potential role of herbal medicines as a novel approach in sepsis treatment/<https://doi.org/10.1016/j.biopha.2021.112337>

20. Karolina Akinosoglou, Georgia Kapsokosta, Maria Mouktaroudi, Nikoletta Rovina, Vassileios Kaldis, Aggelos Stefos, Marina Kontogiorgi, Evangelos Giamarellos-Bourboulis, Charalambos Gogos, on behalf of Hellenic Sepsis Study Group//Diabetes on sepsis outcomes in non-ICU patients: A cohort study and review of the literature/*Journal of Diabetes and Its Complications* 35 (2021) 107765 <https://doi.org/10.1016/j.jdiacomp.2020.107765>

21. Kerina J. Denny, Rodney A. Lea, Ross Lindell-Innes, Larisa M. Haupt, Aaron J. Heffernan, Nicholas R. Harvey, Oliver Hughes, Van T. Cao, Janine Stuart, David L. Paterson, John F. McNamara, Jacobus P.J. Ungerer, Carel J. Pretorius, Lyn R. Griffiths, Jeffrey Lipman//Diagnosing sepsis in the ICU: Comparison of a gene expression signature to pre-existing biomarkers/<https://doi.org/10.1016/j.jcrc.2023.154286> *J CritCare*76(2023) 154286

22. Kondo Y, Umemura Y, Hayashida K, Hara Y, Aihara M, Yamakawa K. Diagnostic value of procalcitonin and presepsin for sepsis in critically ill adult patients: a systematic review and meta-analysis. *J Intensive Care* 2019;7:22. <https://doi.org/10.1186/s40560-019-0374-4>.

23. Liu VX, Fielding-Singh V, Greene JD, Baker JM, Iwashyna TJ, Bhattacharya J, et al. The timing of early antibiotics and hospital mortality in Sepsis. *Am J Respir Crit Care Med* 2017;196:856–63. <https://doi.org/10.1164/rccm.201609-1848OC>.

24. Lukaszewski RA, Jones HE, Gersuk VH, Russell P, Simpson A, Brealey D, et al. Presymptomatic diagnosis of postoperative infection and sepsis using gene expression signatures. *Intensive Care Med* 2022. <https://doi.org/10.1007/s00134-022-06769-z>.

25. Maggioli, E., McArthur, S., Mauro, C., Kieswich, J., Kusters, D.H.M., Reutelingsperger, C.P.M., Yaqoob, M., Solito, E., 2016. Estrogen protects the blood-brain barrier from inflammation-induced disruption and increased lymphocyte

- trafficking. Brain Behav. Immun. 51, 212–222. <https://doi.org/10.1016/j.bbi.2015.08.020>.
26. Martinez ML, Ferrer R, Torrents E, Guillamat-Prats R, Goma G, Suarez D, et al. Impact of source control in patients with severe Sepsis and septic shock. Crit Care Med 2017;45:11–9. <https://doi.org/10.1097/CCM.0000000000002011>.
27. Maslove DM, Shapira T, Tyryshkin K, Veldhoen RA, Marshall JC, Muscedere J. Validation of diagnostic gene sets to identify critically ill patients with sepsis. J Crit Care 2019;49:92–8. <https://doi.org/10.1016/j.jcrc.2018.10.028>.
28. McHugh L, Seldon TA, Brandon RA, Kirk JT, Rapisarda A, Sutherland AJ, et al. A molecular host response assay to discriminate between Sepsis and infectionnegative systemic inflammation in critically ill patients: discovery and validation in independent cohorts. PLoS Med 2015;12:e1001916. <https://doi.org/10.1371/journal.pmed.1001916>.
29. Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD, et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 2015;372:1301–11. <https://doi.org/10.1056/NEJMoa1500896>.
30. Opal SM, Wittebole X. Biomarkers of infection and Sepsis. Crit Care Clin 2020;36:11–22. <https://doi.org/10.1016/j.ccc.2019.08.002>.
31. Paratz JD, Lipman J, Boots RJ, Muller MJ, Paterson DL. A new marker of sepsis post burn injury?*. Crit Care Med 2014;42:2029–36. <https://doi.org/10.1097/CCM.0000000000000400>.
32. Permpikul C, Tongyoo S, Viarasilpa T, Trainarongsakul T, Chakorn T, Udompanturak S. Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A randomized trial. Am J Respir Crit Care Med 2019;199:1097–105. <https://doi.org/10.1164/rccm.201806-1034OC>
33. Prescott, H.C., Angus, D.C., 2018. Enhancing recovery from Sepsis: a review. JAMA 319, 62–75. <https://doi.org/10.1001/jama.2017.17687>.
34. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for Sepsis and septic shock (Sepsis-3). JAMA 2016;315:801–10. <https://doi.org/10.1001/jama.2016.0287>
35. Singer, B.H., Newstead, M.W., Zeng, X., Cooke, C.L., Thompson, R.C., Singer, K., Ghantasala, R., Parent, J.M., Murphy, G.G., Iwashyna, T.J., Standiford, T.J., 2016. Cecal ligation and puncture results in long-term central nervous system myeloid inflammation. PLoS One 11, e0149136. <https://doi.org/10.1371/journal.pone.0149136>.
36. Sweeney TE, Khatri P. Benchmarking Sepsis gene expression diagnostics using public data*. Crit Care Med 2017;45:1–10. <https://doi.org/10.1097/CCM.0000000000002021>.

-
37. Tan M, Lu Y, Jiang H, Zhang L. The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis: a systematic review and meta-analysis. *J Cell Biochem* 2019;120:5852–9. <https://doi.org/10.1002/jcb.27870>.
38. Téblick, A., Peeters, B., Langouche, L., Van den Berghe, G., 2019. Adrenal function and dysfunction in critically ill patients. *Nat. Rev. Endocrinol.* 15, 417–427. <https://doi.org/10.1038/s41574-019-0185-7>.
39. Van Oers JAH, De Jong E, Kemperman H, Girbes ARJ, de Lange DW. Diagnostic accuracy of Procalcitonin and C-reactive protein is insufficient to predict proven infection: a retrospective cohort study in critically ill patients fulfilling the Sepsis-3 criteria. *J Appl Lab Med* 2020;5:62–72. <https://doi.org/10.1373/jalm.2019.029777>.
40. Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, et al. Adjunctive glucocorticoid therapy in patients with septic shock. *N Engl J Med* 2018;378:797–808. <https://doi.org/10.1056/NEJMoa1705835>.
41. Verboom DM, Koster-Brouwer ME, Varkila MRJ, Bonten MJM, Cremer OL. Profile of the SeptiCytE LAB gene expression assay to diagnose infection in critically ill patients. *Expert Rev Mol Diagn* 2019;19:95–108. <https://doi.org/10.1080/14737159.2019.1567333>.
42. Vijayan AL, Vanimaya Ravindran S, Saikant R, Lakshmi S, Kartik R, et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. *J Intensive Care* 2017;5:51
43. Weixin Guo, Zhonghua Wang, Shouhong Wang, Xiaolong Liao, Tiehe Qin //Transcriptome sequencing reveals differential expression of circRNAs in sepsis induced acute respiratory distress syndrome/Life Sciences 278 (2021) 119566 <https://doi.org/10.1016/j.lfs.2021.119566>
44. Wischmeyer PE, McDonald D, Knight R. Role of the microbiome, probiotics, and “dysbiosis therapy” in critical illness. *Curr Opin Crit Care* 2016;22:347–53. <https://doi.org/10.1097/MCC.0000000000000321>.
45. Xinxin Wu, Chenming He, Changya Liu, Xiangru Xu, Caiyu Chen, Hongqiang Yang, Haimei Shi, Yuerong Fei, Yuting Sun, Shuang Zhou, Bangjiang Fang//Mechanisms of JinHong Formula on treating sepsis explored by randomized controlled trial combined with network pharmacology/ <https://doi.org/10.1016/j.jep.2022.116040>.
46. Yupeng Lei, Ruixi Zhou, Xue Mei Sun, Xihong Li//Systematic review and meta-analysis of Xingnaojing treatment for sepsis associated encephalopathy/journal homepage: <http://www.sciencedirect.com/>
47. Zhen Chen, Xinhui Dong, Genglong Liu, Yangpeng Ou, Chuangang Lu, Ben Yang, Xuelian Zhu, Liuer Zuo//Comprehensive characterization of costimulatory molecule gene for diagnosis, prognosis and recognition of immune microenvironment features in sepsis / <https://doi.org/10.1016/j.clim.2022.109179>